This Is MS Multiple Sclerosis Community: Knowledge & Support

I apologize for the double-post, but here's a list of links on Chlamydia pneumoniae, the targeted pathogen in antibiotic treatment, for many at least.

If you read through these you'll be pretty well-informed on CPn.

Here's a list I compiled of many relevant links on Chlamydia pneumoniae:


** Information on Chlamydia pneumoniae in general **
http://herkules.oulu.fi/isbn9514269853/html/x467.html

** Information on Chlamydia pneumoniae and its relationship to human diseases in general **

This article includes neurological diseases and includes the statement, currently ignored by most neurologists, that “chlamydial infections should be included in the differential diagnosis of neurological syndromes.”
http://www.fmtlc.com/images/chronic_dis.pdf

A story from a TN newspaper about a patient at Vanderbilt who had severe MS and had it successfully treated through antibiotic treatment. They found Chlamydia pneumoniae in his spinal fluid:
http://www.tennessean.com/sii/99/04/24/ms24.shtml

Another newspaper article on the treatment of MS with antibiotics:
http://weeklywire.com/ww/02-14-00/nash_cover.html

A very unpolished but interesting page with all kinds of information about antibiotics and MS, mostly from Vanderbilt.
http://home.earthlink.net/~robert016/ms.htm

This is a sub-page of the above address: The owner of the page tracked down many of the patients treated with antibiotics at Vanderbilt, and actually talked or e-mailed with them. Interesting information! http://home.earthlink.net/~robert016/mss.htm

** U.S. Patents **

If you go to http://www.uspto.gov/patft/index.html then you can call up the patents on treatment and diagnosis of Chlamydia pneumoniae.

The patent numbers are 6,838,552, 6,756,369 and for MS specifically, 6,710,033.

he role of CPn in multiple other diseases, including asthma, arthritis, etc: Includes a good explanation of CPn in general:
http://www.asthmastory.com/cp.asp

On treating those with asthma for CPn infection:
http://www.asthmastory.com/faq.asp

As well as http://erj.ersjournals.com/cgi/content/ ... t/15/2/254

For men only (Prostatits): http://www.prostatitis.org/a212000.html

For women mostly (Interstitial cystitis): http://www.hisandherhealth.com/aua2001/ ... ntial.html

Cardiovascular Disease (includes an explanation of how CPn can disseminate throughout the body- good stuff): http://www.theheartattackgerm.com/what%20is.htm

And here’s an article on the “usual” view of Chlamydia pneumoniae as a respiratory pathogen: http://www.emedicine.com/med/topic341.htm

Here is another link, to the abstract regarding the Rogier Hintzen trial from 2003. I have got a better link to it somewhere so I will change it as soon as I unearth it. I will also add others as I come across them.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14681894&dopt=Abstract

Sarah

edit: um, sorry, the link I was thinking of is actually a hard copy of the paper sent from source, so I can't really copy and post it!

Two more links from last year, two more papers soon to be published from Vanderbilt, not sure when yet.


A small double-blind trial of antibiotics from the Vanderbilt team has just been presented at a conference:
Sriram, S., Song, Y., Moses, H., Stratton, C.W., Wolinsky J.: A pilot study to examine the effect of antibiotic therapy on MRI outcomes in relapsing remitting MS. Poster Presentation. Presented at the Annual Meeting of the American Academy of Neurology, San Francisco, CA, 2004.
A regression of lesions was found in treated patients. Antibiotics reduced the level of parenchymal brain shrinkage to rates seen in the unaffected population. The trial was small but fastidious. Interestingly, the antibiotics they used (rifampicin and azithromycin) don't have the anti-inflammatory properties which minocycline and doxycycline do.


Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15164186

Sarah
.

This is a good full text article from The Journal of Immunology, dating back to 2002, from which I quote one small part of the introduction, to inspire you to work through the whole lot, bursting full of CPn and gamma-interferon:



http://www.jimmunol.org/cgi/content/full/169/5/2524

Sarah

Those undergoing anti-chlamydial therapy may want to consider taking nifedipine 30mg 1x/day. See below:

http://www.ncbi.nlm.nih.gov/entrez/quer ... t=Abstract

Macrophage L-type Ca2+ channel antagonists alter Chlamydia pneumoniae MOMP and HSP-60 mRNA gene expression, and improve antibiotic susceptibility.

Azenabor AA, Chaudhry AU, Yang S.

Department of Health Sciences, University of Wisconsin, Milwaukee, WI 53211, USA. aazenabo@uwm.edu

Recent data have shown a unique relationship between Ca2+ signaling in macrophages through L-type channels and the outcome of C. pneumoniae infection of such cells. The present investigation seeks to provide insights into the manner in which macrophage L-type Ca2+ channel operation affects major outer membrane protein (MOMP) and heat shock protein-60 (HSP-60) mRNA gene expression (factors associated with Chlamydia chronicity), and the possible effect of this on antibiotic susceptibility. Intracellular calcium ([Ca2+]i) chelation using varying doses of 1,2-bis (o-aminophenoxy) ethane-N,N,N'N'--tetra acetic acid (acetoxymethyl) ester (BAPTA-AM) induced an increase in MOMP and a decrease in HSP-60 mRNA gene expression. L-type Ca2+ channel antagonists produced an identical but enhanced effect. Since these findings associate specialized Ca2+ channels to Chlamydia chronicity, it was important to determine Ca2+ channel effect on the usual antibiotic refractory form of C. pneumoniae in macrophages. Inhibition of macrophage L-type Ca2+ channel operation improved C. pneumoniae antibiotic susceptibility assessed by decreased inclusion counts or down-regulated MOMP and HSP-60 mRNA gene expression.

These findings provide molecular insights into how specialized Ca2+ channels influence Chlamydia chronic course in macrophages and demonstrates a role for L-type Ca2+ channel inhibitors in enhanced C. pneumoniae susceptibility to antibiotic therapy.

_________________
On Vanderbilt Antibiotic Protocol since January